Protein catalyzed capture agents with tailored performance forin vitroandin vivoapplications
Open Access
- 25 March 2017
- journal article
- research article
- Published by Wiley in Peptide Science
- Vol. 108 (2)
Abstract
We report on peptide‐based ligands matured through the protein catalyzed capture (PCC) agent method to tailor molecular binders forin vitrosensing/diagnostics andin vivopharmacokinetics parameters. A vascular endothelial growth factor (VEGF) binding peptide and a peptide against the protective antigen (PA) protein ofBacillus anthracisdiscovered through phage and bacterial display panning technologies, respectively, were modified with click handles and subjected to iterativein situclick chemistry screens using synthetic peptide libraries. Each azide‐alkyne cycloaddition iteration, promoted by the respective target proteins, yielded improvements in metrics for the application of interest. The anti‐VEGF PCC was explored as a stablein vivoimaging probe. It exhibited excellent stability against proteases and a mean eliminationin vivohalf‐life (T1/2) of 36 min. Intraperitoneal injection of the reagent results in slow clearance from the peritoneal cavity and kidney retention at extended times, while intravenous injection translates to rapid renal clearance. The ligand competed with the commercial antibody for binding to VEGFin vivo. The anti‐PA ligand was developed for detection assays that perform in demanding physical environments. The matured anti‐PA PCC exhibited no solution aggregation, no fragmentation when heated to 100°C, and > 81% binding activity for PA after heating at 90°C for 1 h. We discuss the potential of the PCC agent screening process for the discovery and enrichment of next generation antibody alternatives.Keywords
Funding Information
- Army Institute for Collaborative Biotechnologies (W911NF-09-0001)
This publication has 37 references indexed in Scilit:
- A Cocktail of Thermally Stable, Chemically Synthesized Capture Agents for the Efficient Detection of Anti-Gp41 Antibodies from Human SeraPLOS ONE, 2013
- Nanobodies: Natural Single-Domain AntibodiesAnnual Review of Biochemistry, 2013
- Protease‐resistant peptide design—empowering nature's fragile warriors against HIVPeptide Science, 2012
- Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1Journal of the American Chemical Society, 2011
- Phage display: Concept, innovations, applications and futureBiotechnology Advances, 2010
- Design of an Optimized Scaffold for Affibody MoleculesJournal of Molecular Biology, 2010
- Therapeutic antibodies: successes, limitations and hopes for the futureBritish Journal of Pharmacology, 2009
- Folding and Unfolding Mechanism of Highly Stable Full-Consensus Ankyrin Repeat ProteinsJournal of Molecular Biology, 2008
- Deamidation of model β-turn cyclic peptides in the solid stateJournal of Pharmaceutical Sciences, 2005
- A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal AlkynesAngewandte Chemie International Edition, 2002